Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1938 Eleven Years Survival after Combined Treatment of Surgery, Ultrasound-Guided Radiofrequency Ablation of Liver Metastasis, CT Embolization Plus Somatostatin LAR in a Case with Atypical Carcinoid of the Lung

Introduction: The combination of different therapeutic methods has an important place in the treatment of patients with NET and liver metastasis, ineligible for radical surgery.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Genov J, Terziev I, Petrov I, Grosdinski L, Vladimirov B,

Keywords: atypical carcinoid of the lung, liver metastasis,

#1490 Even Malignant Appendiceal Neuroendocrine Tumors Exhibit No Recurrent Chromosomal Alterations

Introduction: Neuroendocrine tumors (NETs) of the midgut are located in the ileum (iNET), caecum or appendix (aNET). Despite of the similar origin, NETs of the ileum and the appendix behave remarkably different. iNETs show high malignant potential, which manifests with early lymph node or liver metastases. Genetically, the loss of chromosome 18 (Ch18) in 60-74% of cases is the most frequent alteration in iNETs. aNETs are often incidental findings, rarely show metastases, and no chromosomal alterations are known.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sipos B

Authors: Nann D, Nieser M, Sperveslage J, Henopp T, Vokuhl C,

Keywords: NET,

#1408 Epidemiological Factors at Diagnosis in a Large Cohort of Patients with Small Bowel Neurondocrine Tumours

Introduction: The incidence of small bowel Neuroendocrine Tumours (SBNETs) has been increasing. Despite previous reports, epidemiological data regarding several clinical factors are limited.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: TOUMPANAKIS C

Authors: Toumpanakis C, Vlachou E, Wilkins D, Tuck A, Phillips E,

Keywords: Small bowel NETs, epidemiology, diagnosis,

#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs

Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Severi S

Authors: Stefano S, Maddalena S, Ianniello A, Nicolini S, Caroli P,

Keywords: PRRT, GEP-NET, re-treatment,

#993 Analysis of Somatostatin Receptors Expression in Neuroendocrine Tumors

Introduction: Clinical studies have suggested anti-tumor efficacy of somatostatin analog (SSA) in the treatment of neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Li T

Authors: Li T, Qian Z, Ter-Minassian M, Chan J, Brais L,

Keywords: SSTR2, SSA, NET, OS, PFS,